Company intelligence / Profile preview
OncoSec Medical
- Ownership
- Private
- Development stage
- Other
01
Overview
OncoSec's lead candidate TAVO-EP (plasmid encoding IL-12) is in Phase 3 trials for metastatic melanoma. The KEYNOTE-695 trial is evaluating TAVO-EP in combination with Merck's Keytruda in melanoma patients refractory to immune checkpoint therapy. Top-line results for the secondary endpoint (ORR by investigator assessment) were expected in Q4 2022, and primary endpoint results (ORR by blinded independent review) were expected in Q1 2023.
- Therapeutic areas
- Oncology
- Modalities
- Gene therapyDNA-based immunotherapyPlasmid-based therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Merck (for KEYNOTE-695 and KEYNOTE-890 trials with Keytruda)Bristol-Myers Squibb (for trials with Opdivo)
Beyond the preview
Go deeper on OncoSec Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoSec Medical.